^
Association details:
| Biomarker: | MYD88 mutation |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | methotrexate (THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PIM1 and CD79B Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS
Published date:
11/09/2022
Excerpt:
The CDP (including CD79B and/or PIM1mutations) group was identified in 27 cases (67.5%), and the non-CDP (without CD79B and PIM1 mutations) group was identified in 13 cases 32.5%). The CDP group tended to occur in older patients (median age 57.0 vs. 48.4 years, p=0.015). Patients in the CDP group had a significantly longer 2-year overall survival (OS) (76% and 40%, p=0.0372) than those in the non-CDP group...Patients with PIM1 and/or CD79B mutations had favorable long-term survival after high-dose methotrexate-based polychemotherapy.
Source:
Title:
PIM1 and CD79b Mutation Status Impacts the Outcome of Primary Diffuse Large B-cell Lymphoma of the CNS
Published date:
03/09/2022
Excerpt:
Forty cases of primary CNS DLBCL treated with high-dose methotrexate-based (HD-MTX) polychemotherapy were subjected to targeted exome sequencing covering 413 genes, including MYD88, CD79b and PIM1....Mutational analysis recognized two groups. The CDP (including MYD88 and/or CD79b mutations) group was identified in 28 cases (70%), and the non-CDP (without CD79b and PIM1 mutations) group was identified in 12 cases (30%)….Patients in the CDP group had a significantly longer 2-year overall survival (OS) (76% and 40%, p=0.0372) than those in the non-CDP group but not a significantly longer 2-year progression-free survival (PFS) (50.0% and 29%, p=0.078).
